Scarica l'app Stockscreener
112.57
1.05%
1.17
Dopo l'orario di chiusura:
112.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novartis Ag Adr Borsa (NVS) Ultime notizie
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
No room on the ARK? - Morningstar.com.au
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
Novartis Gets CHMP Opinion For Label Expansion Of Fabhalta - Barchart
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart
Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK
Novartis 2017 Financial Results - Novartis
ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily
Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily
Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com
Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar
Novartis Financial Results – Q1 2021 - Novartis
Novartis Financial Results – Q2 2023 - Novartis
World Economic Forum Annual Meeting 2025 - Novartis
Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart
LGBTQI+ inclusion - Novartis
Novartis 2022 Financial Results - Novartis
Novartis at ASH - Novartis
Novartis 2021 Financial Results - Novartis
Novartis Financial Results – Q1 2023 - Novartis
Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
J.P. Morgan Healthcare Conference 2024 - Novartis
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):